期刊文献+

恶性肿瘤恶病质骨骼肌萎缩分子机制研究进展 被引量:4

Progress in the molecular mechanism of skeletal muscle wasting in cancer cachexia
原文传递
导出
摘要 目的:总结国内外对恶性肿瘤恶病质状态下骨骼肌萎缩的分子机制研究进展。方法:应用PubMed和维普期刊资源整合平台,以"恶性肿瘤、恶病质、骨骼肌萎缩、泛素-蛋白酶体途径和自噬信号通路"作为关键词,检索2002-01-01-2013-12-31相关文献。纳入标准:1)恶性肿瘤;2)恶病质;3)骨骼肌萎缩;4)泛素-蛋白酶体途径;5)自噬信号通路。根据纳入标准符合分析的文献33篇。结果:机体在各种刺激下主要通过UPP和ALP降解骨骼肌细胞,ALP在恶病质状态下活性明显升高,UPP可能在恶性肿瘤恶病质中晚期激活。在饥饿和应激等情况下,UPP和ALP可能主要经Akt/PI3K-/mTOR调控;在恶性肿瘤恶病质状态下,FoxO被抑制,骨骼肌萎缩可能主要与NF-κB和p38 MAPK有关。NF-κB能调控E3s转录,并且在Beclin1的基因序列上有相应结合位点;p38MAPK抑制剂SB202190能使E3s及LC3表达下调。结论:对恶性肿瘤恶病质状态下骨骼肌萎缩调控机制的研究将有助于靶向药物的研发,以期改善恶性肿瘤恶病质患者的预后。 OBJECTIVE: To review the progress in the molecular mechanism of skeletal muscle wasting in cancer ca- chexia. METHODS: Use "cancer,cachexia,skeletal muscle wasting/atrophy,ubiquitin-proteasome pathway,autophagy-li- sosomal pathway" as keywords to search for related papers between Jan. lst,2002 and Dec. 31st,2013 in Pubmed and Vip database. Retrieval criteria : 1) cancer; 2) cachexia ; 3) skeletal muscle wasting/atrophy; 3 ) UPP; 4) ALP. Thirty-three papers were included. RESULTS= Skeletal muscle wasting takes place mainly through UPP and ALP in various stimuli. ALP ac- tivity is obviously increased in cancer caehexia. UPP may be activated in advanced stage. In starvation or stress,UPP and ALP may be regulated by Akt/PI3 K-FoxO/mTOR. In cancer cachexia, they may both be regulated by NF-κB and p3813 MAPK pathway. NF-~B up-regulates E3s transcription, and has binding site on Beclinl gene. SB202190 down-regulates E3s and LC3 through p38 MAPK inhibition. CONCLUSIONS: Researches on the molecular mechanisms of skeletal muscle wasting in cancer caehexia contribute to the development of targeted drugs and improvement of the patients prognosis.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第16期1301-1304,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 恶性肿瘤 恶病质 骨骼肌萎缩 泛素-蛋白酶体途径 自噬信号通路 综述文献 cancer cachexia muscle wasting ubiquitin-proteasome pathway autophagy-lisosomal pathway reviewliterature
  • 相关文献

参考文献33

  • 1Evans WJ, Morley JE, Argiles J, et al. Cachexia : a new definition [J]. Clin Nutr,2008,27(6) :793-799.
  • 2Glass DJ. Signaling pathways perturbing muscle mass[J]. Curr Opin Clin Nutr Metab Care,2010,13(3)..225-229.
  • 3Cohen S, Brault J J, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRFl-de- pendent ubiquitylation[J]. Cell Biol, 2009,185(6) : 1083-1095.
  • 4Polge C, Heng AE,Jarzaguet M, et al. Muscle actin is polyubiq- uitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1[J]. FASEB J,2011,25(11) :3790-3802.
  • 5Bao B,Thakur A, Li YW, et al. The immunological contribution of NF-eB within the tumor microenvironment: A potential pro-tective role of zinc as ananti-tumor agent[J]. Biochim Biophys Acta, 2012,1825(2) .. 160-172.
  • 6Roberta M,Serge AL,Jean-Luc L. The translational factor elF3f; the ambivalent eIF3 subunit[J]. Cell Mol Life Sei, 2013,70 (19) : 3603- 3616.
  • 7Op den Kamp CM, Langen RC, Minnaard R, et al. Pre-cachexia in patients with stages I --lll non-small cell lung cancer: systemic inflammatin and functional impairment without activation of skeletal muscle ubiquitin proteasome system[J]. Lung Cancer, 2012,76(1) : 112-117.
  • 8Bossola M, Muscaritoli M,Costelli P, et al. Increased muscle pro- teasome activity correlates with disease severity in gastric cancer patients[J]. Ann Surg,2003,237(3) :384-389.
  • 9Khal J, Hine AV,Fearon KC, et al. Increased expression of pro- teasome subunits in skeletal muscle of cancer patients with weight loss[J]. Int J Biochem Cell Biol, 2005, 37 (10) : 2196- 2206.
  • 10Lokireddy S,Wijesoma IW,Sharma M,et al. Myostatin is a novel tumoral factor that induces cancer cachexia[J]. Biochem J,2012, 446(1) :23-36.

二级参考文献21

  • 1董磊,孙红培.醋酸甲地孕酮对癌症厌食——恶病质综合症的临床疗效[J].中国医药指南,2008,6(17):398-399. 被引量:1
  • 2何陵湘.甲地孕酮对改善鼻咽癌肿瘤患者的生存质量的观察[J].实用医技杂志,2006,13(3):343-345. 被引量:5
  • 3赵艳凤,姜达.癌性恶病质发生的分子机制及其逆转[J].实用肿瘤学杂志,2007,21(2):169-172. 被引量:13
  • 4Fearon KC,Voss AC,Hustead DS.Cancer Cachexia Study Group Definition of cancer cachexia:effect of weight loss,reduced food intake,and systemic inflammation on functional status and prognosis[J].Am J Clin Nutr,2006,83(6):1345-1350.
  • 5崔慧娟 李佩文.醋酸甲地孕酮在晚期肿瘤治疗中的应用进展.国外医学:肿瘤学分册,2001,28(6):473-474.
  • 6Dianliang Z.Probing cancer cachexia-anorexia:recent results with knock-out,transgene andpolyraorphisms.Curr Opin Clin Nutr Metab Care,2009,12:227-231.
  • 7Goll DE,Neti G,Mares SW,et al.Myofibrillar protein turnover:Theproteasome and the calpains.J Anim Sci,2008,86:E19-E35.
  • 8Aulino P,Berardi E,Cardillo VM,et al.Molecular,cellular and physi-ological characterization of the cancer cachexia-inducing C26 coloncarcinoma in mouse.BMC Cancer,2010,10:363.
  • 9Mantovani G,Maccio A,Madeddu C,et al.Phase II nonrandomizedstudy of the efficacy and safety of COX-2 inhibitor celecoxib on pa-tients with cancer cachexia.J Mol Med(Berl),2010,88:85-92.
  • 10Barber MD,Ross JA,Fearon KC.Disordered metabolic response withcancer and its management.World J Surg,2000,24:681-689.

共引文献9

同被引文献40

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部